Sanjay Shukla
President and CEO at aTyr Pharma Inc.
Sits on 1 board. Last updated September 28, 2026
Time on boards
- Boards served
- 1
- Current seats
- 1
- Board service
- 4 years
- Director since
- 2023
4 years of board service in total across 1 board, counting each seat separately. Longest: aTyr Pharma Inc., 3 years.
aTyr Pharma Inc.
Director · President and CEO
Chief executive roles
aTyr Pharma Inc.
· President and CEO
Dates unknown
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Feb 4, 2026 | aTyr Pharma Inc. | Open-market sale | −3,745 | $0.98 | $3,670 |
| Feb 3, 2026 | aTyr Pharma Inc. | Option exercise | +10,375 | — | — |
| Feb 3, 2025 | aTyr Pharma Inc. | Option exercise | +10,375 | — | — |
| May 31, 2024 | aTyr Pharma Inc. | Open-market purchase | +20,000 | $1.81 | $36,200 |
| Feb 5, 2024 | aTyr Pharma Inc. | Option exercise | +10,375 | — | — |
| Dec 12, 2023 | aTyr Pharma Inc. | Open-market purchase | +12,000 | $1.18 | $14,160 |
| Dec 11, 2023 | aTyr Pharma Inc. | Open-market purchase | +3,000 | $1.17 | $3,510 |
| Nov 13, 2023 | aTyr Pharma Inc. | Open-market purchase | +13,578 | $1.11 | $15,072 |
| Nov 10, 2023 | aTyr Pharma Inc. | Open-market purchase | +1,422 | $1.14 | $1,621 |
| Jul 28, 2023 | aTyr Pharma Inc. | Open-market purchase | +15,000 | $2.01 | $30,150 |
| Feb 3, 2023 | aTyr Pharma Inc. | Option exercise | +10,375 | — | — |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.